	US 12,473,355 B2
	Gremlin-1 crystal structure and inhibitory antibody
Neesha Dedi, Slough (GB); Breda Twomey, Slough (GB); Michael John Wright, Slough (GB); Gareth Charles Glyndwr Davies, Slough (GB); and David James Mcmillan, Slough (GB)
Assigned to UCB BIOPHARMA SRL, Brussels (BE)
Filed by UCB BIOPHARMA SRL, Brussels (BE)
Filed on Nov. 6, 2023, as Appl. No. 18/502,188.
Application 18/502,188 is a division of application No. 17/172,109, filed on Feb. 10, 2021, granted, now 11,807,680.
Application 17/172,109 is a division of application No. 16/470,996, granted, now 10,947,304, previously published as PCT/EP2017/083650, filed on Dec. 19, 2017.
Claims priority of application No. 1621635 (GB), filed on Dec. 19, 2016.
Prior Publication US 2024/0076365 A1, Mar. 7, 2024
Int. Cl. A61K 39/00 (2006.01); A61P 9/12 (2006.01); C07K 14/51 (2006.01); C07K 16/22 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/22 (2013.01) [A61P 9/12 (2018.01); C07K 14/51 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07B 2200/13 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

17 Claims

1. A method of treating pulmonary arterial hypertension comprising administering a therapeutically effective amount of a monoclonal anti-Gremlin-1 antibody comprising a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 or a therapeutically effective amount of a pharmaceutical composition thereof to a patient in need thereof.